Bon-Dijon (Powder) Instructions for Use
Marketing Authorization Holder
Moscow Pharmaceutical Factory CJS (Russia)
ATC Code
B05CB04 (Sodium bicarbonate)
Active Substance
Sodium bicarbonate (BP British Pharmacopoeia)
Dosage Form
| Bon-Dijon | Powder for preparation of oral solution and topical application 10 g: pkg. 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for oral administration and topical application white, crystalline, odorless, with a salty-alkaline taste; aqueous solutions have an alkaline reaction.
| 1 sachet | |
| Sodium bicarbonate | 10 g |
10 g – sachets (3) – cardboard packs.
10 g – sachets (5) – cardboard packs.
10 g – sachets (10) – cardboard packs.
Clinical-Pharmacological Group
Acidosis correction preparation for parenteral use
Pharmacotherapeutic Group
Antacid agent
Pharmacological Action
Antacid agent, regulates acid-base balance. It has alkaline properties, increases the alkaline reserve of the blood. When taken orally, it quickly neutralizes hydrochloric acid of gastric juice and has a rapid but short-lived antacid effect.
It irritates the receptors of the gastric mucosa, increases the release of gastrin with secondary activation of secretion, and may cause discomfort in the stomach (due to its distension) and belching.
It has an expectorant effect by reducing the viscosity of sputum due to a shift towards the alkaline side of the reaction of bronchial mucus.
When absorbed, it leads to the development of alkalosis. Alkalinization of urine prevents the precipitation of uric acid in the urinary tract.
It alleviates the symptoms of seasickness and airsickness.
Indications
Metabolic acidosis (including in diabetes mellitus, infections, intoxications, kidney diseases, anesthesia, in the postoperative period); as a symptomatic agent for the relief of heartburn, discomfort in the epigastrium associated with increased acidity of gastric juice; symptomatic treatment of cough with viscous and difficult-to-expectorate sputum in various respiratory tract diseases; seasickness and airsickness.
For topical application: inflammatory diseases of the oral cavity, eyes, upper respiratory tract, for softening earwax.
ICD codes
| ICD-10 code | Indication |
| E87.2 | Acidosis |
| H01.0 | Blepharitis |
| H10 | Conjunctivitis |
| H15 | Diseases of sclera |
| H16 | Keratitis |
| H61.2 | Impacted cerumen |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| K04 | Diseases of pulp and periapical tissues (including periodontitis) |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| K29 | Gastritis and duodenitis |
| R05 | Cough |
| R09.3 | Sputum |
| R10.1 | Pain localized to the upper abdomen |
| R12 | Heartburn |
| T75.3 | Motion sickness |
| ICD-11 code | Indication |
| 5C73.Z | Acidosis, unspecified |
| 9A01.3 | Infectious blepharitis |
| 9A02.Z | Inflammatory disorders of eyelid, unspecified |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A7Z | Diseases of the cornea, unspecified |
| 9B5Z | Disorders of sclera, unspecified |
| AA42 | Impacted cerumen |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA09.Z | Diseases of pulp and periapical tissues, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| MD10 | Abnormal sputum |
| MD12 | Cough |
| MD81.10 | Pain localized in the upper abdomen |
| MD95 | Heartburn |
| NF08.3 | Motion sickness |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For oral administration, dissolve the contents of one sachet (10 g) in half a glass (100 ml) of cool or warm water. Use the prepared solution immediately.
For heartburn and epigastric discomfort, take the solution orally. The single dose is one sachet. Do not use this regimen systematically or for more than a few days without medical supervision.
As an expectorant for cough with viscous sputum, take the solution orally 2-3 times daily. The duration of use is determined by the physician based on clinical need.
For metabolic acidosis, the dosage is individually calculated by a physician based on the severity of acidosis and blood gas parameters. Do not self-treat this condition.
For motion sickness (seasickness, airsickness), take the solution at the first signs of nausea, following the single dose instructions.
For topical application as a mouthwash or gargle for inflammatory diseases of the oral cavity and pharynx, use a 2% solution (dissolve 2 g of powder in 100 ml of water). Rinse 3-4 times daily.
For eye washes in cases of conjunctivitis or other inflammatory conditions, use a 0.5-2% solution. Apply externally only; ensure the solution is sterile.
To soften earwax, instill a few drops of a warm 1-2% solution into the external auditory canal. Do not use if eardrum perforation is suspected.
Adhere strictly to the recommended concentrations and frequencies of use. Consult a physician for treatment beyond a few days or if symptoms persist.
Adverse Reactions
With prolonged use, the development of alkalosis (sometimes uncompensated) is possible, accompanied by loss of appetite, nausea, vomiting, pain in the epigastric region, anxiety, headaches, and in some severe cases, tetanic convulsions; increased blood pressure, flatulence (when taken orally).
Contraindications
Conditions accompanied by the development of metabolic alkalosis, hypernatremia, hypokalemia.
Use in Pregnancy and Lactation
Should be used with caution during pregnancy and breastfeeding.
Use in Renal Impairment
In patients with concomitant kidney diseases, excessive sodium intake causes edema and heart failure.
Special Precautions
It is not recommended for systematic use because when neutralizing hydrochloric acid of the stomach with sodium bicarbonate, carbon dioxide is released, which has an excitatory effect on the receptors of the gastric mucosa, increases the release of gastrin, and may cause a secondary increase in secretion.
Furthermore, with prolonged regular use, alkalinization of urine and an increased risk of phosphate stone formation are possible.
Intensive release of CO2 may provoke perforation of the gastrointestinal tract walls.
In patients with concomitant heart or kidney diseases, excessive sodium intake causes edema and heart failure.
Drug Interactions
With simultaneous use, the excretion of amphetamine in the urine decreases due to an increase in urine pH under the influence of sodium bicarbonate.
When sodium bicarbonate is taken orally against the background of lithium carbonate use in established maintenance doses, a decrease in lithium concentration in blood plasma is possible, which is due to the influence of sodium ions.
With simultaneous use with methotrexate, the excretion of methotrexate in the urine increases and its toxic effect on the kidneys decreases due to an increase in urine pH under the influence of sodium bicarbonate.
With simultaneous oral administration, the absorption of tetracyclines decreases.
Due to an increase in urine pH under the influence of sodium bicarbonate, a delay in the excretion of ephedrine from the body is observed and the risk of side effects increases (tremor, anxiety, sleep disorders, tachycardia).
With intravenous drip administration of sodium bicarbonate, an enhancement of the antihypertensive effect of reserpine is possible.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Ingavirin capsules 90mg, 10pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, lotion solution for external use spray 100ml
Actovegin pills 200mg, 50pcs
Kagocel pills 12mg, 30pcs
Arbidol, capsules 100mg, 40pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, ointment, 30g
Nootropil pills 800mg, 30pcs
Mildronate capsules 500mg, 90pcs
OKI, sachets 80mg 2g, 12pcs
Fenotropil pills 100mg, 60pcs
Picamilon pills 50mg, 60pcs
Daivobet, ointment, 30g
No-spa pills 40mg, 64pcs
Noopept, pills 10mg, 50pcs 